PAIN
Volume 139, Issue 2 , Pages 293-305, 15 October 2008

Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat

  • Shi-Hong Zhang

      Affiliations

    • Department of Pharmacology, School of Medicine, Zhejiang University, Hangzhou, PR China
    • Centre for the Study of Pain, Faculties of Dentistry and Medicine, University of Toronto, 124 Edward Street, Toronto, Ont., Canada M5G 1G6
  • ,
  • Yotam Blech-Hermoni

      Affiliations

    • Centre for the Study of Pain, Faculties of Dentistry and Medicine, University of Toronto, 124 Edward Street, Toronto, Ont., Canada M5G 1G6
    • National Human Genome Research Institute, NIH, Bethesda, MD, USA
  • ,
  • Laura Faravelli

      Affiliations

    • Discovery Department, Newron Pharmaceuticals SpA, Bresso (MI), Italy
  • ,
  • Ze’ev Seltzer

      Affiliations

    • Centre for the Study of Pain, Faculties of Dentistry and Medicine, University of Toronto, 124 Edward Street, Toronto, Ont., Canada M5G 1G6
    • Corresponding Author InformationCorresponding author. Tel.: +1 416 979 4900x4433; fax: +1 416 979 4936.

Received 29 June 2007; received in revised form 18 April 2008; accepted 24 April 2008. published online 26 June 2008.

Abstract 

Ralfinamide is analgesic when applied as a single dose in rodent models of stimulus-evoked chronic pain. However, it is unknown whether its chronic application after nerve injury can suppress spontaneous chronic pain, the main symptom driving patients to seek treatment. In this study ralfinamide was administered to rats at doses producing plasma levels similar to those causing analgesia in pain patients. The analgesic effect was tested on autotomy, a behavior of self-mutilation of a denervated paw that models spontaneous neuropathic pain. Sprague–Dawley male rats (N=10–20/group) underwent transection of the sciatic and saphenous nerves unilaterally. Ralfinamide or its vehicle were administered per os for 7 days preoperatively (80mg/kg; bid), followed by the vehicle or Ralfinamide, until postoperative d42. Autotomy was scored daily until d63. Lasting ‘preemptive analgesia’ was found in rats treated with ralfinamide preoperatively, expressed by delayed autotomy onset (P=0.009) and reduced scores on d63 (P=0.01). Rats treated with ralfinamide (30 or 60mg/kg; bid) from the operation till d42, but not preoperatively, also showed delayed autotomy (P=0.05, P=0.006), and reduced autotomy scores lasting till d63 (P=0.02, P=0.01), for the two doses, respectively. Combining ralfinamide treatments for 7 days preoperatively and 42 days postoperatively also resulted in significantly suppressed scores on d42 and d63 (P=0.005, P=0.001, respectively). Suppression of neuropathic pain-related behavior was likely caused by a combination of mechanisms reported for ralfinamide, including inhibition of Na+ and Ca++ currents in Nav1.3, Nav1.7, Nav1.8, and Cav2.2 channels in rat DRG neurons, inhibition of substance P release from spinal cord synaptosomes, NMDA receptor antagonism and neuroprotection.

Keywords: Neuropathic pain, Nerve-end neuroma, Autotomy, Spontaneous pain behavior, Preemptive analgesia, Na+ channel blocker, Ca++ channel blocker, NMDA receptor blocker

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0304-3959(08)00229-7

doi:10.1016/j.pain.2008.04.020

PAIN
Volume 139, Issue 2 , Pages 293-305, 15 October 2008